Skip to main content
SpringerLink
Log in

The treatment with differentiation- and apoptosis-inducing agent, vesnarinone, of a patient with oral squamous cell carcinoma

  • Published:
Apoptosis Aims and scope Submit manuscript

Abstract

A patient with histopathological recurrent oral cancer with well-differentiated squamous cell carcinoma, was treated with differentiation- and apoptosis-inducing agent, vesnarinone, per os at a dose of 180 mg/day for 56 days and then at a dose of 60 mg/day for 93 days. The vesnarinone administration caused complete remission of the tumour. It has been found by immunohistochemical staining and PCR-SSCP analysis that the recurrent tumour has wild type p53 gene and relative high level of LeY expression as well as DNA fragmentation in the cancer cells, as assessed by nick-end labelling. These findings suggest that the cure of oral squamous cell carcinoma observed in this case might be associated with induction of differentiation and apoptosis of cancer cells by vesnarinone.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. OPC-8212 Multicenter Research Group. A placebo-controlled, randomized, double-blind study of OPC-8212 in patients with mild chronic heart failure. Cardiovas Drugs Therap 1990; 4: 419-426.

    Google Scholar 

  2. Nakai S, Kawai K, Aihara K, et al. Vesnarinone (3,4-dihydro-6-[4-(3,4-dimethoxybenzoyl)-1-piperazinyl]-2 (1H)-quinolinone) as an antitumor agent with differentiation or apoptosis inducing activity in human cancer xenografts in nude mice. Proc 85th Ann Meet Amer Assoc Cancer Res 1994; 35: 404.

    Google Scholar 

  3. Sato M, Harada K, Bando T, et al. Antitumor effect of 3,4-dihydro-6-[4-(3,4-dimethoxybenzoyl)-1-piperazinyl]-2(1H)-quinolinone (vesnarinone). Proc 85th Ann Meet Amer Assoc Cancer Res 1994; 35: 397.

    Google Scholar 

  4. Sato M, Harada K, Yoshida H. Induction of differentiation and LeY antigen expression by treatment with 3,4-dihydro-6-[4-(3,4-dimethoxybenzoyl)-1-piperazinyl]-2(1H)-quinolinone (vesnarinone) in a human salivary cancer cell line. Acta Histochem Cytochem 1994; 27: 591-599.

    Google Scholar 

  5. Sato M, Harada K, Bando T, et al. Characteristics of antitumor activity of 3,4-dihydro-6-[4-(3,4-dimethoxybenzoyl)-1-piperazinyl]-2(1H)-quinolinone (Vesnarinone) against a human adenoid squamous carcinoma-forming cell line grown in athymic nude mice. Cancer Lett 1995; 91: 1-9.

    Google Scholar 

  6. Sato M, Kawamata H, Harada K, et al. Induction of cyclin-dependent kinase inhibitor, p21WAF1, by treatment with 3,4-dihydro-6-[4-(3,4-dimethoxybenzoyl)-1-piperazinyl]-2(1H)-quinolinone (vesnarinone) in a human salivary cancer cell line with mutant p53 gene. Cancer Lett 1997; 112: 181-189.

    Google Scholar 

  7. Sato M, Harada K, Yura Y, et al. Induction of tumor differentiation and apoptosis, and LeY antigen expression in treatment with differentiation-inducing agent, vesnarinone, of a patient with salivary adenoid cystic carcinoma. Apoptosis (in press).

  8. Wahi PN, Cohen B, Luthra UK. Histological typing of oral and oropharyngeal tumors. In: International Histological Classification of Tumors, No. 4. Geneva, Switzerland: WHO, 1971.

    Google Scholar 

  9. Sato M, Harada K, Yoshida H, et al. The therapy for oral squamous cell carcinoma by tegafur and streptococcal agent OK-432 in combination with radiotherapy: Association of the therapeutic effect with differentiation and apoptosis in the cancer cells. Apoptosis (in press).

  10. Hiraishi K, Suzuki K, Hakomori SI, Adachi M. LeY antigen expression is correlated with apoptosis (programmed cell death). Glycobiology 1993; 3: 381-390.

    Google Scholar 

  11. Shi SR, Key MC, Kalra KL. Antigen retrieval in formalin-fixed, paraffin-embedded tissue: an enhancement method for immunohistochemical staining based on microwave oven-heating of tissue sections. J Histochem Cytochem 1991; 39: 741-748.

    Google Scholar 

  12. Hsu S-M, Ralné L, Franger H. Use of avidin-biotin peroxidase complex (ABC) in immunoperoxidase technique: a comparison between ABC and unlabeled antibody (PAP) procedures. J Histochem Cytochem 1981; 29: 577-580.

    Google Scholar 

  13. Abe K, McKibbin J, Hakomori S. The monoclonal antibody directed to difucosylated type 2 chain (Fucα1-2Ga1β1-4[Fuca1-3]GlcNAc: Y determinant). J Biol Chem 1983; 258: 11793-11797.

    Google Scholar 

  14. Visakori T, Kallinoiemi OP, Heikkinen AT, Koivula T, Isola J. Small subgroup of aggressive, highly proliferative prostatic carcinomas defined by p53 accumulation. JNCI 1992; 84: 883-887.

    Google Scholar 

  15. Vojtesek B, Bartek J, Midgley CA, Lane DP. An immunochemical analysis of human nuclear phosphoprotein p53: new monoclonal antibodies and epitope mapping using recombinant p53. J Immunol Methods 1992; 151: 237-244.

    Google Scholar 

  16. Gavrieli Y, Sherman Y, Ben-Sasson SA. Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation. J Cell Biol 1992; 119: 493-501.

    Google Scholar 

  17. Katsuraki K, Chiba W, Matsubara Y, Ikeda S, Ueta C, Kinoshita M. A sensitive and high-resolution method for the detection of mutations in the p53 gene using fluorescence-based PCR-SSCP. Biomedical Res 1995; 16: 273-279.

    Google Scholar 

  18. Hartmann A, Blaszyk H, McGovern RM, et al. p53 gene mutations inside and outside of exons 5–8: the patterns differ in breast and other cancers. Oncogene 1995; 10: 681-688.

    Google Scholar 

  19. Miyamoto G, Sasabe H, Odomi M, Shimizu T. High-performance liquid chromatographic procedures for the determination of a new positive inotropic agent, 3,4-dihydro-6-[4-(3,4-dimethoxybenzoyl)-1-piperazinyl]-2 (1H)-quinolinone, in human plasma and urine. J Chromatogr 1985; 338: 450-455.

    Google Scholar 

  20. Fujii S, Ikenaka K, Fukushima M, Shirasaka T. Effect of uracil and its derivatives on antitumor activity of 5-fluorouracil. Gann 1978; 69: 763-772.

    Google Scholar 

  21. Okamoto H, Shoin S, Koshimura S, Shimizu R. Studies on the anticancer and streptolysin S-forming abilities of hemolytic streptococci. Jpn J Microbiol 1967; 11: 323-336.

    Google Scholar 

  22. Sato M, Yoshida H, Yanagawa T, et al. Effects of intradermal administration of streptococcal preparation OK-432 on interferon and natural killer cell activities in patients with oral cancer. Int J Oral Surg 1984; 13: 7-15.

    Google Scholar 

  23. El-Deiry WA, Tokino T, Velculescu VE, et al. WAF-1, a potential mediator of p53 tumor suppression. Cell 1993; 75: 817-825.

    Google Scholar 

  24. Harper JW, Adami GR, Wei N, Keyomarsi K, Elledge SJ. The p21 Cdk-interacting protein Cip 1 is a potent inhibitor of G1 cyclin dependent kinases. Cell 1993; 75: 805-816.

    Google Scholar 

  25. Waga S, Hannon GJ, Beach D, Stillman S. The p21 inhibitor of cyclin-dependent kinases controls DNA replication by interaction with PCNA. Nature 1994; 369: 574-578.

    Google Scholar 

  26. Missero C, Calautti E, Eckner R, et al. Involvement of the cell-cycle inhibitor Cip/WAF1 and the E1A-associated p300 protein in terminal differentiation. Proc Natl Acad Sci USA 1995; 92: 5451-5455.

    Google Scholar 

  27. Shaw P, Bovey R, Tardy S, Sahli S, Sordat B, Costa J. Induction of apoptosis by wild-type p53 in a human colon tumor-derived cell line. Proc Natl Acad Sci USA 1992; 89: 4495-4499.

    Google Scholar 

  28. Yonish-Rouach E, Resnitzky L, Lotem K, Sachs L, Kimchi A, Oren M. Wild type p53 induces apoptosis of myeloid leukemia cells that is inhibited by interleukin 6. Nature 1991; 352: 345-347.

    Google Scholar 

  29. Shaulsky G, Goldfinger N, Peled A, Rotter V. Involvement of wild type p53 in pre-B cell differentiation in vitro. Proc Natl Acad Sci USA 1991; 88: 8982-8986.

    Google Scholar 

  30. Feinstein E, Gale PB, Reed J, Cannai E. Expression of the normal p53 gene induces differentiation of K562 cells. Oncogene 1992; 7: 1853-1857.

    Google Scholar 

  31. Soddu S, Blandino G, Citro G, et al. Wild-type p53 gene expression induces granulocytic differentiation of HL-60 cells. Blood 1994; 83: 2230-2237.

    Google Scholar 

  32. Ronen D, Schwartz D, Teitz Y, Goldfinger N, Rotter V. Induction of HL-60 cells to undergo apoptosis is determined by high levels of wild-type p53 protein whereas differentiation of the cells is mediated by lower p53 levels. Cell Growth Diff 1996; 7: 21-30.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Second Department of Oral and Maxillofacial Surgery, Tokushima University School of Dentistry, 3 Kuramoto-cho, Tokushima, Japan

    M. Sato, K. Harada, Y. Yura, M. Azuma, H. Kawamata, H. Iga, H. Tsujimoto & H. Yoshida

  2. Cellular Technology Institute, Otsuka Pharmaceutical Co., Ltd, Tokushima, Japan

    M. Adachi

Authors
  1. M. Sato
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. K. Harada
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Y. Yura
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. M. Azuma
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. H. Kawamata
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. H. Iga
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. H. Tsujimoto
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. H. Yoshida
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. M. Adachi
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Sato, M., Harada, K., Yura, Y. et al. The treatment with differentiation- and apoptosis-inducing agent, vesnarinone, of a patient with oral squamous cell carcinoma. Apoptosis 2, 313–318 (1997). https://doi.org/10.1023/A:1026493205097

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/A:1026493205097

Search

Navigation